Frequency Therapeutics Inc   (FREQ)
Other Ticker:  
Price: $0.3000 $0.02 6.082%
Day's High: $0.32 Week Perf: 38.57 %
Day's Low: $ 0.28 30 Day Perf: 11.11 %
Volume (M): 309 52 Wk High: $ 5.59
Volume (M$): $ 93 52 Wk Avg: $1.07
Open: $0.29 52 Wk Low: $0.18

 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 37
 Employees 51
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Frequency Therapeutics Inc
Frequency Therapeutics Inc. is a biotechnology company based in Woburn, Massachusetts, that is focused on developing novel therapies for hearing loss and communication disorders. The company was founded in 2015 by leading experts in regenerative biology and inner ear biology, including Christopher Loose, Robert Langer, and Will McLean. Frequency Therapeutics is currently at the forefront of research into regenerating sensory hair cells in the inner ear, a breakthrough that could revolutionize the treatment of hearing loss.

The company's lead product candidate, FX-322, is a proprietary combination of small molecules designed to activate progenitor cells to differentiate into hair cells in the inner ear. FX-322 is administered via an injection into the middle ear and has the potential to restore hearing loss caused by damage to the hair cells in the inner ear. The clinical trials conducted by Frequency Therapeutics have shown promising results, including improvements in natural hearing ability, increased word recognition, and improvements in speech-in-noise scores.

In addition to FX-322, Frequency Therapeutics is also developing additional therapies for hearing loss and communication disorders. These include FX-701, a drug that targets the STAT3 signaling pathway to promote the differentiation of endogenous progenitor cells into cochlear supporting cells, and a gene therapy that is currently in preclinical development to target hearing loss caused by mutations in specific genes.

Frequency Therapeutics has a strong emphasis on advancing its products through rigorous clinical trials, including randomized, double-blind, placebo-controlled studies. The company has a team of experienced professionals dedicated to researching and developing novel therapies for hearing loss and communication disorders. The company has also received significant funding from leading venture capital firms, including Polaris Partners, Morningside Venture Investments, and Longitude Capital.

Overall, with its cutting-edge technology and a strong focus on research and development, Frequency Therapeutics has the potential to make a significant impact in the field of hearing loss and communication disorders. The company is poised to transform the way these conditions are treated and improve the quality of life for millions of people around the world.

   Company Address: 75 Hayden Avenue Lexington 2421 MA
   Company Phone Number: 315-4600   Stock Exchange / Ticker: NASDAQ FREQ
   FREQ is expected to report next financial results on March 09, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com